Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for glycemic control in type 2 diabetic patients hospitalized with acute coronary syndrome
2014-003298-40Phase 3Terminated
- Sponsor
- Health Research Institute Hospital La Fe
- Start
- Nov 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3 trial of liraglutide in type 2 diabetes mellitus (T2DM) and acute coronary syndrome (ACS) (2 arms), sponsored by Health Research Institute Hospital La Fe. Primary endpoint: Efficacy of liraglutide. Started Nov 2014; status: terminated.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2014-003298-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003298-40.